Adenosine dysfunction and adenosine kinase in epileptogenesis.

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Epilepsy traditionally viewed as a neuronal disorder, with treatments targeting neurons.
• Approximately 30% of epilepsy patients are refractory to current neurocentric pharmacotherapy.
• Emerging research implicates astrocyte dysfunction in epilepsy pathogenesis.

Purpose of the Study:

• To review the role of astrocyte-based adenosine kinase (ADK) in epilepsy.
• To explore ADK as a novel therapeutic target for refractory epilepsy.
• To discuss adenosine augmentation therapies (AATs) for epilepsy.

Main Methods:

• Focus on astrocyte-based enzyme adenosine kinase (ADK) as a key regulator of synaptic adenosine.
• Review of evidence from transgenic animal models showing ADK overexpression triggers seizures.
• Examination of pharmacological inhibition of ADK and its efficacy in seizure suppression.

Main Results:

• Astrogliosis in epileptic brains leads to ADK overexpression and adenosine deficiency.
• ADK overexpression is sufficient to induce seizures in animal models.
• Pharmacological ADK inhibition effectively suppresses seizures resistant to conventional drugs.

Conclusions:

• Astrocyte dysfunction, specifically involving ADK, is a critical factor in epilepsy.
• Targeting ADK offers a promising strategy for novel anti-epileptic therapies.
• Adenosine augmentation therapies (AATs) represent a potential treatment for refractory epilepsy by restoring adenosinergic signaling.